Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 9/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945040 | 0.98 | ITK (0.55) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL4202673 | 0.94 | ITK (0.48) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL13945054 | 0.92 | ITK (0.44) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL13945257 | 0.90 | AURKA (0.53) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL4197055 | 0.90 | PLK4 (0.45) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL4196002 | 0.90 | AURKA (0.47) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL13945056 | 0.89 | ITK (0.44) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL13945160 | 0.88 | AURKA (0.48) | ITKAURKAAURKBGSK3BSRC | |
| SCHEMBL4197962 | 0.88 | AURKA (0.46) | ITKAURKAAURKBPLK4PAK4 | |
| SCHEMBL13945144 | 0.88 | IGF1R (0.41) | ITKAURKAAURKBGSK3BSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008154026-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | ITK 962/4885AURKA 2/4885AURKB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.